Phase-dependent Evaluation of Motor Cortex Excitability With TMS in Stroke
Launched by UNIVERSITY OF MINNESOTA · Jul 16, 2021
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a technique called transcranial magnetic stimulation (TMS) can affect the brain's motor areas in people who have had a stroke. The goal is to understand how the rhythm of brain waves influences the ability to move after a stroke. This study is specifically focused on individuals who have experienced a stroke more than six months ago and are facing challenges with movement.
To participate in this trial, you need to be between the ages of 65 and 74 and have experienced a stroke that has left you with some difficulty moving. It's also important that you are comfortable speaking English. Certain conditions, like having metal implants in your head or neck, recent botulinum toxin treatments for your arm, or a history of seizures, may prevent you from joining the study. If you take part, you can expect to undergo TMS sessions, which are non-invasive and painless, while helping researchers learn more about stroke recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Suffering from chronic stroke, resulting in self-reported motor deficits (stroke occurring more than 6 months before study enrollment)
- • Confident level of English language
- Exclusion Criteria:
- • Metal or electric implant in the head, neck, or chest area
- • Upper extremity botulinum toxin treatment in the last 6 months
- • Pregnancy or breastfeeding
- • Prior occurrence of unprovoked seizure
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Alexander Opitz, PhD
Principal Investigator
University of Minnesota Department of Biomedical Engineering
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials